
Natera Unveils Latest Signatera MRD Data at ESMO 2023: Groundbreaking Insights from Circulate Japan Study
Welcome to the Future of Colorectal Cancer Treatment Introduction Presentations include largest analysis from the GALAXY study in colorectal cancer with updated 24-month disease-free survival data, and expanded Signatera readout in rectal cancer AUSTIN, Texas–(BUSINESS WIRE)–Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced it will present new data on its…